EGFR and non-small cell lung carcinoma: Oritinib overcomes T790M-mediated drug resistance in NSCLC and inhibits WT-EGFR, EGFRL858R, EGFRL861Q, EGFRL858R/T790M, EGFRd746-750, and EGFRd746-750/T790M kinases.